ReviewCureus2026
Recent Updates and Advancements in the Diagnosis and Management of Plasma Cell Dyscrasias.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma cell dyscrasias (PCDs) encompass a heterogeneous group of disorders ranging from asymptomatic precursor states such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) to overt multiple myeloma (MM), primary plasma cell leukemia, and systemic amyloidosis. This review is based on a structured search of PubMed, Scopus, Cochrane Library, and Web of Science for literature published between 2015 and 2025, supplemented by reference screening and major international myeloma guidelines to ensure comprehensive coverage of recent advancements. Recent years have witnessed remarkable progress in understanding disease biology, refining diagnostic tools, and expanding therapeutic strategies. Advances in genomics and cytogenetics have deepened insight into clonal evolution and prognostic markers, while next-generation flow cytometry, mass spectrometry, and high-sensitivity serum free light chain assays are revolutionizing disease detection and minimal residual disease monitoring. Parallel improvements in imaging, including whole-body MRI and novel PET tracers, enhance accuracy in disease assessment, while artificial intelligence-driven models hold promise for predictive analytics and personalized care. Therapeutically, immunotherapies including monoclonal antibodies, bispecific antibodies, and chimeric antigen receptor T (CAR-T) cell therapies have transitioned from salvage settings to frontline use, providing deeper and more durable responses. Risk-adapted approaches, improved transplant strategies, and novel maintenance regimens are reshaping the standard of care. Advances also extend to the management of non-myeloma PCDs, supportive care, and survivorship, underscoring the importance of patient-centered approaches. Despite these gains, challenges persist in overcoming therapy resistance, managing costs, and ensuring equitable global access to novel treatments. Looking forward, integration of multi-omics with artificial intelligence, expansion of collaborative clinical trials, and strategies balancing cure vs. disease control will be pivotal in optimizing outcomes. This review synthesizes current evidence and highlights emerging directions shaping the evolving landscape of PCD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.